98 related articles for article (PubMed ID: 8387028)
21. Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system.
Michaud-Levesque J; Rolland Y; Demeule M; Bertrand Y; Béliveau R
Biochim Biophys Acta; 2005 Apr; 1743(3):243-53. PubMed ID: 15843038
[TBL] [Abstract][Full Text] [Related]
22. Soluble urokinase receptor from fibrosarcoma HT-1080 cells.
Lau HK; Kim M
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):473-8. PubMed ID: 7841301
[TBL] [Abstract][Full Text] [Related]
23. Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells.
Schmitt M; Chucholowski N; Busch E; Hellmann D; Wagner B; Goretzki L; Jänicke F; Günzler WA; Graeff H
Semin Thromb Hemost; 1991 Jul; 17(3):291-302. PubMed ID: 1724574
[TBL] [Abstract][Full Text] [Related]
24. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices.
Kroon ME; Koolwijk P; van Goor H; Weidle UH; Collen A; van der Pluijm G; van Hinsbergh VW
Am J Pathol; 1999 Jun; 154(6):1731-42. PubMed ID: 10362798
[TBL] [Abstract][Full Text] [Related]
25. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
26. Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynold LM
Adv Exp Med Biol; 1999; 462():399-412. PubMed ID: 10599442
[TBL] [Abstract][Full Text] [Related]
27. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.
Møller LB; Pöllänen J; Rønne E; Pedersen N; Blasi F
J Biol Chem; 1993 May; 268(15):11152-9. PubMed ID: 8388383
[TBL] [Abstract][Full Text] [Related]
28. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor.
Anichini E; Fibbi G; Pucci M; Caldini R; Chevanne M; Del Rosso M
Exp Cell Res; 1994 Aug; 213(2):438-48. PubMed ID: 8050501
[TBL] [Abstract][Full Text] [Related]
29. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
Lengyel E; Wang H; Gum R; Simon C; Wang Y; Boyd D
Oncogene; 1997 May; 14(21):2563-73. PubMed ID: 9191056
[TBL] [Abstract][Full Text] [Related]
30. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
Guiducci S; Del Rosso A; Cinelli M; Perfetto F; Livi R; Rossi A; Gabrielli A; Giacomelli R; Iori N; Fibbi G; Del Rosso M; Cerinic MM
Arthritis Res Ther; 2005; 7(6):R1244-53. PubMed ID: 16277677
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine phosphorylation of human urokinase-type plasminogen activator.
Barlati S; Paracini F; Bellotti D; De Petro G
FEBS Lett; 1991 Apr; 281(1-2):137-40. PubMed ID: 1901800
[TBL] [Abstract][Full Text] [Related]
32. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.
Carmeliet P; Moons L; Dewerchin M; Rosenberg S; Herbert JM; Lupu F; Collen D
J Cell Biol; 1998 Jan; 140(1):233-45. PubMed ID: 9425170
[TBL] [Abstract][Full Text] [Related]
33. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
[TBL] [Abstract][Full Text] [Related]
34. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
[TBL] [Abstract][Full Text] [Related]
35. Two-chain urokinase, receptor, and type 1 inhibitor in cultured human mesangial cells.
Glass WF; Kreisberg JI; Troyer DA
Am J Physiol; 1993 Mar; 264(3 Pt 2):F532-9. PubMed ID: 8384415
[TBL] [Abstract][Full Text] [Related]
36. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.
Evans CP; Elfman F; Parangi S; Conn M; Cunha G; Shuman MA
Cancer Res; 1997 Aug; 57(16):3594-9. PubMed ID: 9270033
[TBL] [Abstract][Full Text] [Related]
38. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
[TBL] [Abstract][Full Text] [Related]
39. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.
Piedagnel R; Tiger Y; Lelongt B; Ronco PM
J Cell Physiol; 2006 Feb; 206(2):394-401. PubMed ID: 16155905
[TBL] [Abstract][Full Text] [Related]
40. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
